Results 11 to 20 of about 49,720 (263)

Acute Myeloid Leukemia

open access: yesApollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone   +2 more
openaire   +3 more sources

Advances in acute myeloid leukemia [PDF]

open access: yesBMJ, 2021
ABSTRACTAcute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and disease progression have led to novel therapies for AML.
Laura F, Newell, Rachel J, Cook
openaire   +2 more sources

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

open access: yesHaematologica, 2010
Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao   +6 more
doaj   +1 more source

Targeting the MLL complex in acute leukemia [PDF]

open access: yes, 2014
Chromosomal rearrangements leading mostly to fusion oncoproteins of the Mixed Lineage Leukemia (MLL) gene occur in about 10% of all patients with acute leukemia and are often associated with poor clinical outcome, emphasizing the need for new treatment ...
Méreau, Hélène
core   +1 more source

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

open access: yesHaematologica, 2012
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried   +9 more
doaj   +1 more source

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]

open access: yes, 2000
At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Mittermueller, J.   +5 more
core   +1 more source

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

open access: yesHaematologica, 2014
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin   +18 more
doaj   +1 more source

Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population

open access: yesHaematologica, 2009
Background Biphenotypic acute leukemia is a rare disorder that is difficult to diagnose. It displays features of both myeloid and lymphoid lineage. There is still a lack of studies in biphenotypic acute leukemia in a Chinese population. We present here a
Xiao-Qian Xu   +9 more
doaj   +1 more source

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia

open access: yesFrontiers in Immunology, 2022
Acute myeloid leukemia is the most common acute leukemia in adults, with accumulation of abundant blasts and impairment of hematogenic function. Despite great advances in diagnosis and therapy, the overall survival of patients with acute myeloid leukemia
Xianfeng Ouyang   +2 more
doaj   +1 more source

Acute Myeloid Leukemia and Acute Promyelocytic Leukemia

open access: yesHematology, 2003
AbstractThe therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as
Bob, Löwenberg   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy